Biogen
Executive Summary
Purchase of 50% interest in West German firm Bioferon Biochemische Substanzen aimed at facilitating entry of Biogen's gamma interferon into West German and other markets, according to Biogen. Bioferon, which was a wholly owned subsidiary of Rentschler Pharmaceutical (West Germany), markets a beta interferon product, Fiblaferon, in West Germany for life threatening viral infections. Biogen says Fiblaferon, produced through traditional technologies, is "the first interferon product in the world to receive full regulatory approval.".
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.